Arbutus
Warminster, Pennsylvania, United States · Biopharma, Biotechnology, Healthcare
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Warminster, Pennsylvania, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (ABUS)
- Website
- www.arbutusbio.com
- Company page
Recent activity at Arbutus
- : SEC 8-K (8.01): On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website, reflecting potential new strategic directions or updates on their business operations. This presentation is significant for stakeholders as it may contain insights into the company's future plans or performance metrics. A copy of this presentation is included as Exhibit 99.1 in the filing, suggesting its importance for shareholder communications and engagement. This event pertains to the disclosure of ongoing corporate activities that could influence investor perception and market behavior.
- : SEC 8-K (8.01): On October 22, 2026, Arbutus Biopharma Corporation announced via a press release that the U.S. Food and Drug Administration has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor. This significant development allows the Company to proceed with clinical trials for AB-101, which is expected to advance its drug development pipeline. The press release also details the implications for the Company's research and potential market positioning moving forward, indicating strategic importance in the competitive landscape of immune-oncology.
- : SEC 8-K (8.01): On August 21, 2026, Arbutus Biopharma Corporation announced plans to launch a modified 'Dutch auction' tender offer to purchase up to US$230 million in value of its common shares, with a price range set between US$5.00 and US$5.75 per share. The tender offer has not yet commenced, and the company has indicated that there are no assurances it will proceed under the terms outlined. This announcement is significant for shareholders as it represents an opportunity for them to sell their shares back to the company at a predetermined range, potentially impacting share liquidity and overall market sentiment. The official commencement date of the tender offer will trigger additional regulatory filings with the SEC and Canadian authorities.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
About Arbutus: questions and answers
What does Arbutus do?
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing
Where is Arbutus headquartered?
Arbutus is headquartered in Warminster, Pennsylvania, United States.
What is the latest news on Arbutus?
On Aug 21, 2026, SEC 8-K (8.01): On November 12, 2026, Arbutus Biopharma Corporation posted an updated corporate presentation on its website, reflecting potential new strategic directions or updates on their business operations. This presentation is significant for stakeholders as it may contain insights into the co
Is Arbutus a public company?
Yes. Arbutus is publicly traded under the ticker ABUS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy